↓ Skip to main content

Cochrane Database of Systematic Reviews

Intravenous immunoglobulin for myasthenia gravis

Overview of attention for article published in Cochrane database of systematic reviews, December 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

policy
1 policy source
twitter
2 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
128 Dimensions

Readers on

mendeley
215 Mendeley
Title
Intravenous immunoglobulin for myasthenia gravis
Published in
Cochrane database of systematic reviews, December 2012
DOI 10.1002/14651858.cd002277.pub4
Pubmed ID
Authors

Philippe Gajdos, Sylvie Chevret, Klaus V Toyka

Abstract

Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). This is an update of a review first published in 2003 and last updated in 2007.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 215 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 <1%
Colombia 1 <1%
Brazil 1 <1%
Unknown 211 98%

Demographic breakdown

Readers by professional status Count As %
Other 26 12%
Student > Bachelor 23 11%
Student > Master 22 10%
Researcher 20 9%
Student > Doctoral Student 18 8%
Other 55 26%
Unknown 51 24%
Readers by discipline Count As %
Medicine and Dentistry 100 47%
Nursing and Health Professions 14 7%
Agricultural and Biological Sciences 9 4%
Pharmacology, Toxicology and Pharmaceutical Science 9 4%
Neuroscience 6 3%
Other 23 11%
Unknown 54 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2021.
All research outputs
#4,208,412
of 22,953,506 outputs
Outputs from Cochrane database of systematic reviews
#6,674
of 12,333 outputs
Outputs of similar age
#43,647
of 279,978 outputs
Outputs of similar age from Cochrane database of systematic reviews
#93
of 192 outputs
Altmetric has tracked 22,953,506 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,333 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.6. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 192 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.